Decapeptide Combi-Therapy of (resistant) steroidal cancers
Steroid-related cancers have the highest incidence among tumors and its market potential for Europe and U.S.A. is estimated to be at least US$ 2.4 bn p.a. Scientists at the University of Göttingen developed novel proprietary decapeptidic antagonists to target GnRH-II receptor (which is highly expressed in steroidal cancers like e.g. breast, ovarian, endometrium and prostate carcinomas), which could be used in a combination cancer therapy and which potentially could also be used to treat malignant melanoma.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-151
Contact
Dr. Jens-Peter Horst
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Detector for continuously monitoring toxic gases
The material could be made as a thin coating to analyze air quality in industrial or home settings over time. Most systems used to detect toxic gases in industrial or…
On the way for an active agent against hepatitis E
In order to infect an organ, viruses need the help of the host cells. “An effective approach is therefore to identify targets in the host that can be manipulated by…
A second chance for new antibiotic agent
Significant attempts 20 years ago… The study focused on the protein peptide deformylase (PDF). Involved in protein maturation processes in cells, PDF is essential for the survival of bacteria. However,…
